|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||
| 化学式 | C16H14BrN3O3 |
||||||||||
| 分子量 | 376.2 | CAS No. | 211555-04-3 | ||||||||
| Solubility (25°C)* | 体外 | DMSO | 75 mg/mL (199.36 mM) | ||||||||
| Water | Insoluble | ||||||||||
| Ethanol | Insoluble | ||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||
| 製品説明 | WHI-P154 is a potent JAK3 inhibitor with IC50 of 1.8 μM, no activity against JAK1 or JAK2, also inhibits EGFR, Src, Abl, VEGFR and MAPK, prevents Stat3, but not Stat5 phosphorylation. |
|---|---|
| in vitro | WHI-P154 is first described as a JAK3 inhibitor that displays no activity at JAK1 or JAK2. This compound inhibits STAT1 activation, iNOS expression and NO production in macrophages in vitro. But it is proved that this chemical also inhibits other common kinases including EGFR, Src, Abl, VEGFR, MAPK and PI3-K and induces apoptosis in human glioblastoma cell lines. [1] It inhibits glioblastoma cell adhesion and migration in the context of ECM.[2] This compound exhibits significant cytotoxicity against U373 and U87 human glioblastoma cell lines, causing apoptotic cell death at micromolar concentrations. The in vitro antiglioblastoma activity of this chemical is amplified > 200-fold and rendered selective by conjugation to recombinant human epidermal growth factor (EGF). In vitro treatment with EGF-P154 results killing of glioblastoma cells at nanomolar concentrations with an IC50 of 813 nM, whereas no cytotoxicity against EGF-R-negative leukemia cellsis observed, even at concentrations as high as 100 mM.[3] |
| in vivo | The in vivo administration of EGF-P154 results in delayed tumor progression and improved tumor-free survival in a severe combined immunodeficient mouse glioblastoma xenograft model. Whereas none of the control mice remain alive tumor-free beyond 33 days (median tumor-free survival, 19 days) and all control mice have tumors that rapidly progress to reach an average size of > 500 mm3 by 58 days, 40% of mice treated for 10 consecutive days with 1 mg/kg/day this compound remain alive and free of detectable tumors for more than 58 days with a median tumor-free survival of 40 days. The tumors developing in the remaining 60% of the mice never reache a size > 50 mm3.[3] |
| キナーゼアッセイ | Kinase assays | |
|---|---|---|
| WHI-P154 is tested in kinase assays. The panel of kinases is selected to broadly cover the kinome, providing a good approximation of specificity. For all kinases, recombinant rat (IKKβ) or human (all others), full-length or GST-kinase domain fusion proteins, are used. This compound is inactive (concentration that inhibits response by 50% [IC50] > 30 μM) for the following kinases: AKT, AuroraA, cdk2, cdk6, CHK1, FGFR1, GSK3b, IKKb, IKKi, INSR, MAPK1, MAPKAP-K2, MASK, MET, PAK4, PDK1, PKCb, ROCK1, TaoK3, TrkA. | ||
| 細胞アッセイ | 細胞株 | U87, U737 |
| 濃度 | 0.1-250 μM | |
| 反応時間 | 24-36 h | |
| 実験の流れ | Cells are seeded into a 96-well plate at a density of 2.5×104 cells/well and incubated for 36 h at 37 ℃ before drug exposure. On the day of treatment, culture medium is carefully aspirated from the wells and replaced with fresh medium containing the quinazoline compounds WHI-P154 at concentrations ranging from 0.1 μM to 250 μM. Triplicate wells are used for each treatment. The cells are incubated with this compound for 24hours to 36hours at 37 ℃ in a humidified 5% CO2 atmosphere. To each well, 10 μL of MTT (final concentration, 0.5 mg/mL) is added, and the plate are incubated at 37 ℃ for 4 h. Than solubilized overnight at 37 ℃ in a solution containing 10% SDS in 0.01 M HCL. The absorbance of each well is measured in a microplate reader at 570 nm. | |
| 動物実験 | 動物モデル | SCID Xenograft Model of Human Glioblastoma (U737) |
| 投薬量 | 0.5 mg/kg or 1 mg/kg for 10 days | |
| 投与方法 | i.p. | |
|

,

Data from [Data independently produced by , , J Mol Med, 2018, doi:10.1007/s00109-018-1724-8]

Data from [Data independently produced by , , Biol Open, 2018, 7(1)]
| Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis [ Nat Commun, 2023, 14(1):6908] | PubMed: 37903763 |
| Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis [ Nat Commun, 2023, 14(1):6908] | PubMed: 37903763 |
| Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells [ Int J Mol Sci, 2023, 10.3390/ijms241813863] | PubMed: 37762164 |
| Tyrosine Kinase Inhibitor Profiling Using Multiple Forskolin-Responsive Reporter Cells [ Int J Mol Sci, 2023, 24(18)13863] | PubMed: 37762164 |
| Establishment and characterization of immortalized sweat gland myoepithelial cells [ Sci Rep, 2022, 12(1):7] | PubMed: 34997030 |
| Interleukin 6 trans-signaling is a critical driver of lung allograft fibrosis [ Am J Transplant, 2021, 21(7):2360-2371] | PubMed: 33249747 |
| Revisiting Aldehyde Oxidase Mediated Metabolism in Drug-like Molecules: An Improved Computational Model [ J Med Chem, 2020, 31] | PubMed: 32191458 |
| A novel human colon signet-ring cell carcinoma organoid line: establishment, characterization and application [ Carcinogenesis, 2020, 41(7):993-1004] | PubMed: 31740922 |
| IL-21 promotes osteoblastic differentiation of human valvular interstitial cells through the JAK3/STAT3 pathway [ Int J Med Sci, 2020, 17(18):3065-3072] | PubMed: 33173427 |
| Interleukin-23 receptor signaling mediates cancer dormancy and radioresistance in human esophageal squamous carcinoma cells via the Wnt/Notch pathway [Zhou Y, et al. J Mol Med, 2018, 10.1007/s00109-018-1724-8] | PubMed: 30483821 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。